Skip to main content
PAS 2024 Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Conference Ticketed Event
Pre-Conference Ticketed Event
APA Award Winner
APA Award Winner
APS Award Winner
APS Award Winner
ASPN Award Winner
ASPN Award Winner
SPR Award Winner
SPR Award Winner
On Demand Presentation
On Demand Presentation
Poster Icons
SPR Award Winner
SPR Award Winner
Back
Evaluation ViewAttendees 46
Debate/Pro-Con Discussion

Academic and Research Skills

Allergy, Immunology and Rheumatology

Critical Care

General Pediatrics

Hematology/Oncology

Hospital Medicine

Infectious Diseases

Pulmonology

Trainee
Session Type: Debate/Pro-Con Discussion

Hot Controversies in Pediatric Lung Infections: Debates that Could Change your Practice

Sunday, May 5, 2024
11:00 AM – 12:30 PM ET
Location: Metro Toronto Convention Centre: 205
CE: Live CME: 1.5

Selected By: PIDS
Disclosure(s):
Joshua Wolf, MBBS, PhD: Karius Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator); Merck Inc (Terminated, September 1, 2023) (Products/Services: Research Support including clinical trials & the principal or named investigator); Pfizer Inc (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator)

Session

Description: Targeted at pulmonologists, and subspecialist or generalist pediatricians, these 3 rapidfire debates will address current controversies in management of pulmonary infections in children. The focus is on practical and applicable analysis of available data, and attempting to provide some consensus at the end. They will feature established and rising stars in the world of Infectious Diseases,

The topics are: 1. That bronchoalveolar lavage should be routinely performed in profoundly immunocompromised children with suspected lung infection; 2. That inhaled antibiotics should be used more frequently for treatment of children with complicated lung infections; 3. That there is no role for empiric atypical therapy for children with community-acquired pneumonia unless they have a positive test for atypical bacteria.

Learning Objectives:

  • Appraise evidence for and against routine bronchoalveolar lavage in immunocompromised children with suspected lung infection.
  • Summarize the role and targets of inhaled antibiotics for treatment of lung infections in children.
  • Determine the role of empiric atypical therapy for children with community-acquired pneumonia.

Presentations:

  • 11:00 AM – 11:13 AM ET
    Routine bronchoalveolar lavage in profoundly immunocompromised children with suspected lung infection - Pro

    Speaker: Diego R. Hijano, MD, MSc (he/him/his) – St. Jude Children's Research Hospital

  • 11:13 AM – 11:26 AM ET
    Routine bronchoalveolar lavage in profoundly immunocompromised children with suspected lung infection - Con

    Speaker: Pratik A. Patel, MD (he/him/his) – Emory/Children's Healthcare of Atlanta

  • 11:26 AM – 11:39 AM ET
    Inhaled antibiotics for treatment of children with complicated lung infections - Pro

    Speaker: Shane J. Cross, PharmD – St. Jude Children's Research Hospital

  • 11:39 AM – 11:52 AM ET
    Inhaled antibiotics for treatment of children with complicated lung infections - Con

    Speaker: Tonya Scardina, PharmD, BCIDP (she/her/hers) – Ann & Robert H. Lurie Children's Hospital of Chicago

  • 11:52 AM – 12:05 PM ET
    Avoid empiric atypical therapy for children with community-acquired pneumonia - Pro

    Speaker: Joshua Wolf, MBBS, PhD (he/him/his) – St. Jude Children's Research Hospital

  • 12:05 PM – 12:18 PM ET
    Avoid empiric atypical therapy for children with community-acquired pneumonia - Con

    Speaker: Elizabeth Lloyd, MD (she/her/hers) – University of Michigan Medical School